Some people with lupus will develop a condition called Antiphospholipid Syndrome (APS). APS can lead to blood clots, and for pregnant women with lupus, pregnancy complications. We talk with Dr. Jane ...

Phase III ALLEGORY study met primary and all key secondary endpoints with Gazyva/Gazyvaro, an anti-CD20 monoclonal antibody ...

"Roche’s Phase III trial of Gazyva/Gazyvaro for SLE meets primary endpoint" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

Chimeric antigen receptor T-cell therapy has exhibited “compelling” efficacy and safety in lupus, allowing 84% of patients to ...

The results of the ALLEGORY trial of Gazyva (obinutuzumab) suggest that the anti-CD20 antibody could have broad utility in ...

A new approach targets the B-cell pathway with bispecific antibodies, building on decades of research that establishes the role of B cells and self-reactive antibodies in lupus, systemic sclerosis, ...

Investing.com -- The U.S. Food and Drug Administration (FDA) has approved Roche Holding AG’s (SIX:RO) Gazyva/Gazyvaro (obinutuzumab) for treating adult patients with active lupus nephritis who are ...

In a small observational study, telitacicept use was associated with improvement in renal and hematologic parameters in patients with lupus nephritis and nephrotic syndrome. Telitacicept use is ...

(HealthDay News) — Metabolic syndrome is common in young, premenopausal women with systemic lupus erythematosus (SLE), and chloroquine appears to protect against metabolic syndrome in these women, ...

Systemic lupus erythematosus is a lifelong condition that can cause irreversible damage to the major organs in the body, leading to life-threatening complications. These pivotal results are ...